Stocktoria
Amneal Pharmaceuticals, Inc. AMRX
Amneal Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0B | $2.8B | $2.4B | $2.2B | $2.1B | $2.0B | $1.6B | $1.7B | $1.0B |
| Gross profit | $1.1B | $1.0B | $820.6M | $784.7M | $769.0M | $628.4M | $353.0M | $716.4M | $526.2M |
| R&D expense | $186.2M | $190.7M | $163.9M | $195.7M | $201.8M | $179.9M | $188.0M | $194.2M | $171.4M |
| SG&A expense | $526.8M | $476.4M | $429.7M | $399.7M | $365.5M | $326.7M | $289.6M | $227.8M | $109.0M |
| Operating income | $394.1M | $249.3M | $204.4M | -$94.9M | $152.7M | $91.2M | -$248.7M | -$19.7M | $245.1M |
| Income tax | $11.3M | $18.9M | $8.5M | $6.7M | $11.2M | -$104.4M | $383.3M | -$1.4M | $2.0M |
| Net income | $72.1M | -$116.9M | -$84.0M | -$270.6M | $13.2M | $67.8M | -$603.6M | -$19.7M | $0 |
| EPS (diluted) | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 | $0.61 | $-2.74 | $-0.16 | — |
| Operating cash flow | $340.0M | $295.1M | $345.6M | $65.1M | $241.8M | $379.0M | $1.7M | $250.2M | $234.2M |
| Free cash flow | $269.9M | $243.2M | $302.4M | $18.7M | $194.1M | $322.6M | -$45.5M | $167.1M | $139.4M |
| Cash & equivalents | $282.0M | $110.6M | $91.5M | $26.0M | $247.8M | $341.4M | $151.2M | $213.4M | $74.2M |
| Inventory | $606.3M | $612.5M | $581.4M | $530.7M | $489.4M | $490.6M | $381.1M | $457.2M | $284.0M |
| Total assets | $3.7B | $3.5B | $3.5B | $3.8B | $3.9B | $4.0B | $3.7B | $4.4B | $1.3B |
| Total liabilities | — | — | — | — | — | — | — | — | $0 |
| Shareholders' equity | -$71.3M | -$109.5M | $20.0M | $298.4M | $367.0M | $344.9M | $346.8M | $896.4M | $0 |
Growth · year-over-year · Revenue CAGR 14.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +8.0% | +16.7% | +8.2% | +5.7% | +5.1% | +22.5% | -2.2% | +60.9% | — |
| Net income growth | — | — | — | -2155.6% | -80.6% | — | — | — | — |
| EPS growth | — | — | — | -1328.6% | -88.5% | — | — | — | — |
| Free cash flow growth | +11.0% | -19.6% | +1517.5% | -90.4% | -39.8% | — | -127.2% | +19.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.